Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Leveraging eMed Empathetic AI technology and a seamless digital experience, eMeds platform provides employers auditable ROI through cost avoidance and improved population health
Funding P.F
Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial
Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)
These are incredibly helpful for comparison, allowing Eddie to see how your health is trending
